Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Teucrium Corn Fund (CORN) vs Mesoblast Limited (MESO) Price & Performance

Teucrium Corn FundTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Teucrium Corn Fund vs Mesoblast Limited — how do they compare? Teucrium Corn Fund trades at $17.8, while Mesoblast Limited trades at $18.19 (market cap $2.12B). The key difference: Mesoblast Limited is trading nearer its 52-week high, Teucrium Corn Fund nearer its low. Which is the better fit depends on your goals.

CORNMESO
Sector
Commodities - Metals/AgricultureTechnology
52-Week High
$19.12$20.96
52-Week Low
$16.46$10.96
Market Cap
$2.12B
Enterprise Value
$2.13B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Teucrium Corn Fund

CORN stock trades at $17.55 with a slight 0.4% daily gain, showing bullish technical momentum with strong moving average support. The company's financial ratios remain undisclosed in current data, limiting fundamental visibility. Recent partnership news with Hormel Foods for CORN NUTS brand licensing provides potential growth catalyst, while technical indicators suggest continued upward pressure with key resistance at $18.

Outlook remains cautiously optimistic given bullish technical signals and brand expansion opportunities, though limited financial transparency presents valuation challenges. Key risks include commodity price volatility and competitive pressures in the snack food sector. Investors should monitor upcoming earnings for fundamental clarity while technical momentum supports near-term upside potential.

Mesoblast Limited

MESO trades at $16.22, up 5.05% today, with a bullish technical outlook from moving averages but mixed oscillators. The company shows strong gross margins of 80.52% but remains unprofitable with a net income margin of -144.33%. Recent news highlights commercial progress, including Ryoncil revenue of $36 million in Q4 2026 and pivotal Phase 3 trial milestones for chronic low back pain.

The outlook is cautiously optimistic, driven by FDA-approved Ryoncil's revenue growth and pipeline advancements, but high valuation (P/S 30.52) and persistent losses pose risks. Analyst consensus leans buy (45.46%), yet investors face volatility from clinical trial outcomes and cash burn concerns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Teucrium Corn Fund

CORN is a commodity ETF that provides exposure to the price of corn futures. It uses a laddered investment strategy across multiple benchmark contracts to help minimize the impact of contango and roll costs in the agricultural market.

Read more on CORN

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO